Cargando…

Targeting allosteric sites of human aromatase: a comprehensive in-silico and in-vitro workflow to find potential plant-based anti-breast cancer therapeutics

Recent findings suggested several allosteric pockets on human aromatase that could be utilised for the development of new modulators able to inhibit this enzyme in a new mechanism. Herein, we applied an integrated in-silico-based approach supported by in-vitro enzyme-based and cell-based validation...

Descripción completa

Detalles Bibliográficos
Autores principales: Alhadrami, Hani A., Sayed, Ahmed M., Melebari, Sami A., Khogeer, Asem A., Abdulaal, Wesam H., Al-Fageeh, Mohamed B., Algahtani, Mohammad, Rateb, Mostafa E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759730/
https://www.ncbi.nlm.nih.gov/pubmed/34139914
http://dx.doi.org/10.1080/14756366.2021.1937145
Descripción
Sumario:Recent findings suggested several allosteric pockets on human aromatase that could be utilised for the development of new modulators able to inhibit this enzyme in a new mechanism. Herein, we applied an integrated in-silico-based approach supported by in-vitro enzyme-based and cell-based validation assays to select the best leads able to target these allosteric binding sites from a small library of plant-derived natural products. Chrysin, apigenin, and resveratrol were found to be the best inhibitors targeting the enzyme’s substrate access channel and were able to produce a competitive inhibition with IC(50) values ranged from 1.7 to 15.8 µM. Moreover, they showed a more potent antiproliferative effect against ER+ (MCF-7) than ER- one (MDA-MB-231) cell lines. On the other hand, both pomiferin and berberine were the best hits for the enzyme’s haem-proximal cavity producing a non-competitive inhibition (IC(50) 15.1 and 21.4 µM, respectively) and showed selective antiproliferative activity towards MCF-7 cell lines.